Published in J Mol Model on July 24, 2009
A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings. J Comput Aided Mol Des (2013) 0.95
Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies. J Phys Chem B (2012) 0.89
Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations. Int J Mol Sci (2012) 0.88
Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir. J Comput Aided Mol Des (2012) 0.88
Molecular dynamics simulation in virus research. Front Microbiol (2012) 0.87
Molecular dynamic simulation insights into the normal state and restoration of p53 function. Int J Mol Sci (2012) 0.78
Insights into the structural function of the complex of HIV-1 protease with TMC-126: molecular dynamics simulations and free-energy calculations. J Mol Model (2011) 0.77
New insights into the in silico prediction of HIV protease resistance to nelfinavir. PLoS One (2014) 0.77
Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism. J Mol Graph Model (2014) 0.76
Reduced surface: an efficient way to compute molecular surfaces. Biopolymers (1996) 10.62
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 4.80
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
HIV-protease inhibitors. N Engl J Med (1998) 4.42
Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. J Mol Biol (2003) 3.89
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc (2001) 2.55
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol (2004) 2.21
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 2.15
Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem (2006) 1.69
Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry (1991) 1.63
Computational study of protein specificity: the molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci U S A (2001) 1.58
Molecular dynamics and continuum solvent studies of the stability of polyG-polyC and polyA-polyT DNA duplexes in solution. J Biomol Struct Dyn (1998) 1.48
Adaptive inhibitors of the HIV-1 protease. Prog Biophys Mol Biol (2005) 1.47
Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. J Med Chem (2007) 1.39
Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain. J Mol Biol (2008) 1.38
Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design. Biopolymers (2006) 1.14
Binding of antifusion peptides with HIVgp41 from molecular dynamics simulations: quantitative correlation with experiment. Proteins (2007) 1.02
Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs (1998) 1.02
Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations. Proteins (2004) 1.00
Evaluating the potency of HIV-1 protease drugs to combat resistance. Proteins (2008) 0.97
Selectivity of neutral/weakly basic P1 group inhibitors of thrombin and trypsin by a molecular dynamics study. Chemistry (2008) 0.93
A computational analysis of the binding affinities of FKBP12 inhibitors using the MM-PB/SA method. Proteins (2006) 0.93
New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: candidates for clinical development. J Med Chem (1998) 0.93
Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens. AIDS Patient Care STDS (2002) 0.83
Molecular insight into the interaction between IFABP and PA by using MM-PBSA and alanine scanning methods. J Phys Chem B (2007) 0.82
Conformational analysis of TMC114, a novel HIV-1 protease inhibitor. J Chem Inf Model (2008) 0.81
Pharmacological considerations in antiretroviral therapy. Antivir Ther (1998) 0.79
Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human alpha-thrombin. Biophys J (2007) 0.77
Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: molecular dynamics simulations and free energy calculations. J Mol Model (2009) 0.86
A computational analysis of the binding model of MDM2 with inhibitors. J Comput Aided Mol Des (2010) 0.85
Insights into scFv:drug binding using the molecular dynamics simulation and free energy calculation. J Mol Model (2010) 0.81
Heavy-ion conformal irradiation in the shallow-seated tumor therapy terminal at HIRFL. Med Biol Eng Comput (2007) 0.79
Non-randomized mtDNA damage after ionizing radiation via charge transport. Sci Rep (2012) 0.77
Time-dependent quantum wave packet study of the Ar+H2+→ArH(+)+H reaction on a new ab initio potential energy surface for the ground electronic state (1(2)A'). J Chem Phys (2013) 0.75
One-pot synthesis of reduced graphene oxide-cadmium sulfide nanocomposite and its photocatalytic hydrogen production. Phys Chem Chem Phys (2011) 0.75
New approach to oximes through reduction of nitro compounds enabled by visible light photoredox catalysis. Org Lett (2013) 0.75
A divide-and-conquer approach to quad remeshing. IEEE Trans Vis Comput Graph (2013) 0.75
High LET radiation enhances nocodazole Induced cell death in HeLa cells through mitotic catastrophe and apoptosis. J Radiat Res (2011) 0.75
Effectiveness of respiratory-gated radiotherapy with audio-visual biofeedback for synchrotron-based scanned heavy-ion beam delivery. Phys Med Biol (2016) 0.75
[The effect of budesonide inhalation suspension via transnasal nebulization to the volume of bleeding during endoscopic sinus surgery]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi (2014) 0.75
Effect of electrostatic polarization and bridging water on CDK2-ligand binding affinities calculated using a highly efficient interaction entropy method. Phys Chem Chem Phys (2017) 0.75
N,N-Dimethylaminobenzoates enable highly enantioselective Sharpless dihydroxylations of 1,1-disubstituted alkenes. Org Biomol Chem (2014) 0.75